- Previous Close
0.0500 - Open
0.0490 - Bid 0.0540 x --
- Ask 0.0560 x --
- Day's Range
0.0490 - 0.0530 - 52 Week Range
0.0340 - 0.1050 - Volume
250,001 - Avg. Volume
172,180 - Market Cap (intraday)
15.614M - Beta (5Y Monthly) 0.14
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0300 - Earnings Date Feb 26, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Control Bionics Limited, together with its subsidiaries, engages in the research, development, commercialization, and sale of assistive communications technology systems in Australia, North America, and internationally. The company offers NeuroNode Trilogy, NeuroNode Duo, and Eye-gaze Duo systems that allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. It also provides Cosmos Connect, a small portable control device that can be used with a Windows display device; NeuroNode, a wireless wearable sensor that gives the user the ability to access their technology by bioelectric signals or spatial movements; Uno Touch, a speech generating device; and NeuroNode Duo, a wireless sensor. The company was formerly known as Control Bionics Holdings Pty Limited and changed its name to Control Bionics Limited in September 2020. Control Bionics Limited was incorporated in 2005 and is headquartered in Cremorne, Australia.
www.controlbionics.comRecent News: CBL.AX
View MorePerformance Overview: CBL.AX
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CBL.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CBL.AX
View MoreValuation Measures
Market Cap
15.61M
Enterprise Value
15.10M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.33
Price/Book (mrq)
2.42
Enterprise Value/Revenue
2.98
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-131.48%
Return on Assets (ttm)
-48.68%
Return on Equity (ttm)
-98.08%
Revenue (ttm)
5.28M
Net Income Avi to Common (ttm)
-6.95M
Diluted EPS (ttm)
-0.0300
Balance Sheet and Cash Flow
Total Cash (mrq)
972.23k
Total Debt/Equity (mrq)
7.02%
Levered Free Cash Flow (ttm)
-2.47M